Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antenatal Corticosteroids in Early Threatened Preterm Birth (22-23w6d)
NCT02351310Phase 3Withdrawn
- Sponsor
- Pediatrix Medical Group
- Start
- Nov 2015
- Primary completion
- Nov 2015
- Modality
- Orthosteric Ligands
01
Overview
Phase 3, randomised, double-blind trial of betamethasone in preterm birth, sponsored by Pediatrix Medical Group. Primary endpoint: Composite Neonatal Morbidity and Mortality at 30 days. Planned start Nov 2015; status: withdrawn.
02
Drugs
betamethasone
03
Conditions
preterm birth
Beyond the preview
Go deeper on NCT02351310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351310.